# NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
Canonical URL: https://biopharmsignal.com/news/NXGL/nexgel-to-present-at-planet-microcap-conference-las-vegas-on-june-16th-18th
Ticker: NXGL
Company: NEXGEL
Source: NEXGEL
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.nexgel.com
## Summary

LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider…...

## Article Body
LANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Planet MicroCap Conference on June 16 – 18, 2026, in Las Vegas, NV.

Planet MicroCap Las Vegas 2026 Dates: June 16-18, 2026 Location: Bellagio Hotel & Casino, Las Vegas, NV Booth: #517 Presentation Day and Time: Wednesday, June 17, 2026, at 1:30 P.M. PT Presentation Location: Track 3 - Da Vinci 3 Webcast: https://ir.nexgel.com/news-events/events-presentations

To schedule a one-on-one investor meeting with Mr. Levy, please contact KCSA Strategic Communications at Nexgel@kcsa.com .

About NEXGEL, INC.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 Nexgel@kcsa.com

Source: NEXGEL, INC. Released June 4, 2026
## Recent Company News
- 2026-06-25 13:46 EST — [NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th](https://biopharmsignal.com/news/NXGL/nexgel-to-present-at-planet-microcap-conference-las-vegas-on-june-16th-18th) — Source: NEXGEL
- 2026-06-25 13:46 EST — [NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration](https://biopharmsignal.com/news/NXGL/nexgel-reports-positive-data-from-randomized-single-center-irb-study-to-evaluate-the-effectiveness-and-safety-of-a-hydrogel-laser-treatment-patch-in-laser-hair-removal-with-a-95-6-reduction-in-plume-concentration) — Source: NEXGEL
- 2026-06-25 13:46 EST — [NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical](https://biopharmsignal.com/news/NXGL/nexgel-appoints-dave-hazard-as-vice-president-of-sales-for-bionx-surgical) — Source: NEXGEL
- 2026-06-25 13:46 EST — [NEXGEL To Report First Quarter 2026 Financial Results on May 15th](https://biopharmsignal.com/news/NXGL/nexgel-to-report-first-quarter-2026-financial-results-on-may-15th) — Source: NEXGEL
- 2026-06-25 13:46 EST — [NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products](https://biopharmsignal.com/news/NXGL/nexgel-signs-definitive-agreement-to-license-and-acquire-transformative-portfolio-of-commercial-stage-regenerative-biomaterial-products) — Source: NEXGEL
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)